Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer

Share :
Published: 26 Oct 2026
Views: 1163
Rating:
Save
Dr Jacob Sands - Dana-Farber Cancer Institute, Boston, USA

Prof Jacob Sands speaks to ecancer about the primary analysis of the phase III DeLLphi-305 trial, which evaluated tarlatamab plus durvalumab versus durvalumab alone as first-line maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease had not progressed following initial treatment with durvalumab, platinum-based chemotherapy and etoposide.

Among 563 patients, adding tarlatamab to durvalumab significantly improved overall survival, with median overall survival increasing from 12.7 to 21.1 months.

Prof Sands says the combination also significantly improved progression-free survival, extending median progression-free survival from 1.9 to 7.4 months, and increased the objective response rate from 4.1% to 26.4%.

Grade 3 or higher treatment-emergent adverse events occurred in 46.8% of patients receiving the combination and 40.6% receiving durvalumab alone.

Cytokine release syndrome occurred in 49.6% of patients treated with tarlatamab plus durvalumab, while immune effector cell-associated neurotoxicity syndrome occurred in 1.1%; these events were primarily low grade, with no fatal events reported.

Dr Sands speculates that these findings could establish tarlatamab plus durvalumab as a new standard of care for first-line maintenance treatment of ES-SCLC.

This information is intended for health care professionals only. The information is not intended for US health care professionals.

Related Videos

Tarlatamab's role in SCLC

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Tarlatamab's role in SCLC ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
15 Oct 2026

Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC

Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )
13 Oct 2026

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC ( Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA )
28 Sep 2026

Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC

Dr Chul Kim - Georgetown Cancer Institute, Washington, USA
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC ( Dr Chul Kim - Georgetown Cancer Institute, Washington, USA )
28 Sep 2026

Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC

Dr Jonathan Goldman - University of California Los Angeles, Los Angeles, USA
Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC ( Dr Jonathan Goldman - University of California Los Angeles, Los Angeles, USA )
18 Sep 2026

JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )
18 Sep 2026

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )
31 May 2026

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management? ( Dr Daniel Portik - European Organisation for Research and Treatment of Cancer, Brussels, Belgium )
11 May 2026

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia
Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC ( Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia )
16 Apr 2026